Effect of Allopurinol on Mono and Co-administration With Statins on Platelets Reactivity on Diabetic Patiets Treated With Aspirin and Insulin

NCT03195153 — Phase 4, Unknown, 200 participants, University of Roma La Sapienza

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  
RegistryNCT03195153
StatusUnknown
PhasePhase 4
Study typeInterventional; randomized, crossover, masking: single, treatment
Enrollment200 (Estimated)
SponsorUniversity of Roma La Sapienza (Other)
ConditionsDiabetes Mellitus Type 2 Platelets Reactivity Statin
InterventionsAtorvastatin 80mg, ALLOPURINOL 300 MG, Atorvastatin 80mg AND allopurinol 300 mg (Drug)
Datesstart 2017-03-28, primary completion 2017-06-23 (estimated), completion 2017-07-15 (estimated), first posted 2017-06-22, last updated 2017-06-22
Locations1 site in Italy

Related Papers Related Patents Related Grants Related Experts
All trials for Diabetes Mellitus Type 2 Platelets Reactivity Statin All trials of Atorvastatin 80mg All trials of ALLOPURINOL 300 MG

-Summary

Diabetes mellitus is associated with an increased risk of cardiovascular disease. Substantial clinical and experimental evidence suggest that both diabetes and insulin resistance cause a combination of endothelial dysfunctions, which may diminish the anti-atherogenic role of the vascular endothelium. Therefore, in patients with diabetes or insulin resistance, endothelial dysfunction may be a critical early target for preventing atherosclerosis and cardiovascular disease. It has been implicated as an independent risk factor for cardiovascular disease and premature cardiovascular mortality for patients with type 1 and type 2 diabetes mellitus, as well as for patients with essential hypertension. A complete biochemical understanding of the mechanisms by which hyperglycemia causes vascular functional and structural changes associated with the diabetic milieu still eludes us. In recent years, the numerous biochemical and metabolic pathways postulated to have a causal role in the pathogenesis of diabetic vascular disease have been distilled into several unifying hypotheses. The role of chronic hyperglycemia in the development of diabetic microvascular complications and in neuropathy has been clearly established. However, the biochemical or cellular links between elevated blood glucose levels, and the vascular lesions remain incompletely understood. A number of trials have demonstrated that statins therapy as well as angiotensin converting enzyme inhibitors is associated with improvements in endothelial function in diabetes. Although antioxidants provide short-term improvement of endothelial function in humans, all studies of the effectiveness of preventive antioxidant therapy have been disappointing. Actually, control of hyperglycemia thus remains the best way to improve endothelial function and to prevent atherosclerosis and other cardiovascular complications of diabetes.

Expand all sections  ·  Collapse all

+Arms and interventions

ArmTypeInterventionsDescription
statin onlyExperimentalDrug: Atorvastatin 80mg30 DAYS OF STATIN THERAPY ATORVASTATIN 80 MG)
allopurinol onlyExperimentalDrug: ALLOPURINOL 300 MG30 DAYS OF ALLOPURINOL (300 MG)
statin and allopurinolExperimentalDrug: Atorvastatin 80mg AND allopurinol 300 mg30 DAYS OF CO-ADMINISTRATION OF ATORVASTATIN AND ALLOPURINOL
  • Atorvastatin 80mg (Drug): 30 DAYS OF atorvastatin 80 mg
  • ALLOPURINOL 300 MG (Drug): 30 DAYS OF ALLOPURINOL 300 MG
  • Atorvastatin 80mg AND allopurinol 300 mg (Drug): 30 days of atorvastatin and allopurinol 300 mg

+Outcome measures

Primary outcomes

  • Assessment of platelet reaction units Absolute changes in platelet reactivity (expressed as P2Y(12) reaction units by the point-of-care VerifyNow assay [Accumetrics, San Diego, California] After 30 days of treatment with each drug [fter 30 days of treatment with each drug]: Absolute changes in platelet reactivity (expressed as P2Y(12) reaction units by the point-of-care VerifyNow assay \[Accumetrics, San Diego, California\]

+Eligibility

Sex: All, ages: 18 Years to 80 Years, accepts healthy volunteers

Inclusion Criteria:

* diabetic patient;
* therapy with aspirin and insulin;
* patient well responders

Exclusion Criteria:

* not diabetic patient;
* patients in dual antiplatelet therapy;
* patient with severe renal failure;
* patient poor responders

+Locations (1)

FacilityCityCountryStatus
Policlinico Umberto IRome, RomaItalyRecruiting